NuCana Encouraging Data on NUC-7738 Combination in Melanoma

 

Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety Profile

https://www.globenewswire.com/news-release/2024/09/14/2946232/0/en/NuCana-Presents-Encouraging-Data-on-NUC-7738-in-Combination-with-Pembrolizumab-in-PD-1-Inhibitor-Refractory-and-Resistant-Melanoma-Patients-at-the-ESMO-Congress-2024.html